GABA, glutamine, glutamate oxidation and succinic semialdehyde dehydrogenase expression in human gliomas

Zoltán Hujber, Gergő Horváth, Gábor Petővári, Ildikó Krencz, Titanilla Dankó, Katalin Mészáros, Hajnalka Rajnai, N. Szoboszlai, William P.J. Leenders, A. Jeney, L. Tretter, A. Sebestyén

Research output: Article

Abstract

BACKGROUND: Bioenergetic characterisation of malignant tissues revealed that different tumour cells can catabolise multiple substrates as salvage pathways, in response to metabolic stress. Altered metabolism in gliomas has received a lot of attention, especially in relation to IDH mutations, and the associated oncometabolite D-2-hydroxyglutarate (2-HG) that impact on metabolism, epigenetics and redox status. Astrocytomas and oligodendrogliomas, collectively called diffuse gliomas, are derived from astrocytes and oligodendrocytes that are in metabolic symbiosis with neurons; astrocytes can catabolise neuron-derived glutamate and gamma-aminobutyric acid (GABA) for supporting and regulating neuronal functions. METHODS: Metabolic characteristics of human glioma cell models - including mitochondrial function, glycolytic pathway and energy substrate oxidation - in relation to IDH mutation status and after 2-HG incubation were studied to understand the Janus-faced role of IDH1 mutations in the progression of gliomas/astrocytomas. The metabolic and bioenergetic features were identified in glioma cells using wild-type and genetically engineered IDH1-mutant glioblastoma cell lines by metabolic analyses with Seahorse, protein expression studies and liquid chromatography-mass spectrometry. RESULTS: U251 glioma cells were characterised by high levels of glutamine, glutamate and GABA oxidation. Succinic semialdehyde dehydrogenase (SSADH) expression was correlated to GABA oxidation. GABA addition to glioma cells increased proliferation rates. Expression of mutated IDH1 and treatment with 2-HG reduced glutamine and GABA oxidation, diminished the pro-proliferative effect of GABA in SSADH expressing cells. SSADH protein overexpression was found in almost all studied human cases with no significant association between SSADH expression and clinicopathological parameters (e.g. IDH mutation). CONCLUSIONS: Our findings demonstrate that SSADH expression may participate in the oxidation and/or consumption of GABA in gliomas, furthermore, GABA oxidation capacity may contribute to proliferation and worse prognosis of gliomas. Moreover, IDH mutation and 2-HG production inhibit GABA oxidation in glioma cells. Based on these data, GABA oxidation and SSADH activity could be additional therapeutic targets in gliomas/glioblastomas.

Original languageEnglish
Number of pages1
JournalJournal of experimental & clinical cancer research : CR
Volume37
Issue number1
DOIs
Publication statusPublished - nov. 7 2018

Fingerprint

Glutamate-5-Semialdehyde Dehydrogenase
Succinate-Semialdehyde Dehydrogenase
Glutamine
Glioma
gamma-Aminobutyric Acid
Mutation
Astrocytoma
Glioblastoma
Astrocytes
Energy Metabolism
Glutamic Acid
Smegmamorpha
Oligodendroglioma
Neurons
Physiological Stress
Symbiosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

GABA, glutamine, glutamate oxidation and succinic semialdehyde dehydrogenase expression in human gliomas. / Hujber, Zoltán; Horváth, Gergő; Petővári, Gábor; Krencz, Ildikó; Dankó, Titanilla; Mészáros, Katalin; Rajnai, Hajnalka; Szoboszlai, N.; Leenders, William P.J.; Jeney, A.; Tretter, L.; Sebestyén, A.

In: Journal of experimental & clinical cancer research : CR, Vol. 37, No. 1, 07.11.2018.

Research output: Article

Hujber, Zoltán ; Horváth, Gergő ; Petővári, Gábor ; Krencz, Ildikó ; Dankó, Titanilla ; Mészáros, Katalin ; Rajnai, Hajnalka ; Szoboszlai, N. ; Leenders, William P.J. ; Jeney, A. ; Tretter, L. ; Sebestyén, A. / GABA, glutamine, glutamate oxidation and succinic semialdehyde dehydrogenase expression in human gliomas. In: Journal of experimental & clinical cancer research : CR. 2018 ; Vol. 37, No. 1.
@article{e076f9bb13fb4bc58ce818fd1f82c5f1,
title = "GABA, glutamine, glutamate oxidation and succinic semialdehyde dehydrogenase expression in human gliomas",
abstract = "BACKGROUND: Bioenergetic characterisation of malignant tissues revealed that different tumour cells can catabolise multiple substrates as salvage pathways, in response to metabolic stress. Altered metabolism in gliomas has received a lot of attention, especially in relation to IDH mutations, and the associated oncometabolite D-2-hydroxyglutarate (2-HG) that impact on metabolism, epigenetics and redox status. Astrocytomas and oligodendrogliomas, collectively called diffuse gliomas, are derived from astrocytes and oligodendrocytes that are in metabolic symbiosis with neurons; astrocytes can catabolise neuron-derived glutamate and gamma-aminobutyric acid (GABA) for supporting and regulating neuronal functions. METHODS: Metabolic characteristics of human glioma cell models - including mitochondrial function, glycolytic pathway and energy substrate oxidation - in relation to IDH mutation status and after 2-HG incubation were studied to understand the Janus-faced role of IDH1 mutations in the progression of gliomas/astrocytomas. The metabolic and bioenergetic features were identified in glioma cells using wild-type and genetically engineered IDH1-mutant glioblastoma cell lines by metabolic analyses with Seahorse, protein expression studies and liquid chromatography-mass spectrometry. RESULTS: U251 glioma cells were characterised by high levels of glutamine, glutamate and GABA oxidation. Succinic semialdehyde dehydrogenase (SSADH) expression was correlated to GABA oxidation. GABA addition to glioma cells increased proliferation rates. Expression of mutated IDH1 and treatment with 2-HG reduced glutamine and GABA oxidation, diminished the pro-proliferative effect of GABA in SSADH expressing cells. SSADH protein overexpression was found in almost all studied human cases with no significant association between SSADH expression and clinicopathological parameters (e.g. IDH mutation). CONCLUSIONS: Our findings demonstrate that SSADH expression may participate in the oxidation and/or consumption of GABA in gliomas, furthermore, GABA oxidation capacity may contribute to proliferation and worse prognosis of gliomas. Moreover, IDH mutation and 2-HG production inhibit GABA oxidation in glioma cells. Based on these data, GABA oxidation and SSADH activity could be additional therapeutic targets in gliomas/glioblastomas.",
keywords = "2-hydroxyglutarate, Bioenergetics, GABA, Glioma, Glutamine, IDH1 mutation, Succinic semialdehyde dehydrogenase",
author = "Zolt{\'a}n Hujber and Gergő Horv{\'a}th and G{\'a}bor Petőv{\'a}ri and Ildik{\'o} Krencz and Titanilla Dank{\'o} and Katalin M{\'e}sz{\'a}ros and Hajnalka Rajnai and N. Szoboszlai and Leenders, {William P.J.} and A. Jeney and L. Tretter and A. Sebesty{\'e}n",
year = "2018",
month = "11",
day = "7",
doi = "10.1186/s13046-018-0946-5",
language = "English",
volume = "37",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - GABA, glutamine, glutamate oxidation and succinic semialdehyde dehydrogenase expression in human gliomas

AU - Hujber, Zoltán

AU - Horváth, Gergő

AU - Petővári, Gábor

AU - Krencz, Ildikó

AU - Dankó, Titanilla

AU - Mészáros, Katalin

AU - Rajnai, Hajnalka

AU - Szoboszlai, N.

AU - Leenders, William P.J.

AU - Jeney, A.

AU - Tretter, L.

AU - Sebestyén, A.

PY - 2018/11/7

Y1 - 2018/11/7

N2 - BACKGROUND: Bioenergetic characterisation of malignant tissues revealed that different tumour cells can catabolise multiple substrates as salvage pathways, in response to metabolic stress. Altered metabolism in gliomas has received a lot of attention, especially in relation to IDH mutations, and the associated oncometabolite D-2-hydroxyglutarate (2-HG) that impact on metabolism, epigenetics and redox status. Astrocytomas and oligodendrogliomas, collectively called diffuse gliomas, are derived from astrocytes and oligodendrocytes that are in metabolic symbiosis with neurons; astrocytes can catabolise neuron-derived glutamate and gamma-aminobutyric acid (GABA) for supporting and regulating neuronal functions. METHODS: Metabolic characteristics of human glioma cell models - including mitochondrial function, glycolytic pathway and energy substrate oxidation - in relation to IDH mutation status and after 2-HG incubation were studied to understand the Janus-faced role of IDH1 mutations in the progression of gliomas/astrocytomas. The metabolic and bioenergetic features were identified in glioma cells using wild-type and genetically engineered IDH1-mutant glioblastoma cell lines by metabolic analyses with Seahorse, protein expression studies and liquid chromatography-mass spectrometry. RESULTS: U251 glioma cells were characterised by high levels of glutamine, glutamate and GABA oxidation. Succinic semialdehyde dehydrogenase (SSADH) expression was correlated to GABA oxidation. GABA addition to glioma cells increased proliferation rates. Expression of mutated IDH1 and treatment with 2-HG reduced glutamine and GABA oxidation, diminished the pro-proliferative effect of GABA in SSADH expressing cells. SSADH protein overexpression was found in almost all studied human cases with no significant association between SSADH expression and clinicopathological parameters (e.g. IDH mutation). CONCLUSIONS: Our findings demonstrate that SSADH expression may participate in the oxidation and/or consumption of GABA in gliomas, furthermore, GABA oxidation capacity may contribute to proliferation and worse prognosis of gliomas. Moreover, IDH mutation and 2-HG production inhibit GABA oxidation in glioma cells. Based on these data, GABA oxidation and SSADH activity could be additional therapeutic targets in gliomas/glioblastomas.

AB - BACKGROUND: Bioenergetic characterisation of malignant tissues revealed that different tumour cells can catabolise multiple substrates as salvage pathways, in response to metabolic stress. Altered metabolism in gliomas has received a lot of attention, especially in relation to IDH mutations, and the associated oncometabolite D-2-hydroxyglutarate (2-HG) that impact on metabolism, epigenetics and redox status. Astrocytomas and oligodendrogliomas, collectively called diffuse gliomas, are derived from astrocytes and oligodendrocytes that are in metabolic symbiosis with neurons; astrocytes can catabolise neuron-derived glutamate and gamma-aminobutyric acid (GABA) for supporting and regulating neuronal functions. METHODS: Metabolic characteristics of human glioma cell models - including mitochondrial function, glycolytic pathway and energy substrate oxidation - in relation to IDH mutation status and after 2-HG incubation were studied to understand the Janus-faced role of IDH1 mutations in the progression of gliomas/astrocytomas. The metabolic and bioenergetic features were identified in glioma cells using wild-type and genetically engineered IDH1-mutant glioblastoma cell lines by metabolic analyses with Seahorse, protein expression studies and liquid chromatography-mass spectrometry. RESULTS: U251 glioma cells were characterised by high levels of glutamine, glutamate and GABA oxidation. Succinic semialdehyde dehydrogenase (SSADH) expression was correlated to GABA oxidation. GABA addition to glioma cells increased proliferation rates. Expression of mutated IDH1 and treatment with 2-HG reduced glutamine and GABA oxidation, diminished the pro-proliferative effect of GABA in SSADH expressing cells. SSADH protein overexpression was found in almost all studied human cases with no significant association between SSADH expression and clinicopathological parameters (e.g. IDH mutation). CONCLUSIONS: Our findings demonstrate that SSADH expression may participate in the oxidation and/or consumption of GABA in gliomas, furthermore, GABA oxidation capacity may contribute to proliferation and worse prognosis of gliomas. Moreover, IDH mutation and 2-HG production inhibit GABA oxidation in glioma cells. Based on these data, GABA oxidation and SSADH activity could be additional therapeutic targets in gliomas/glioblastomas.

KW - 2-hydroxyglutarate

KW - Bioenergetics

KW - GABA

KW - Glioma

KW - Glutamine

KW - IDH1 mutation

KW - Succinic semialdehyde dehydrogenase

UR - http://www.scopus.com/inward/record.url?scp=85056398297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056398297&partnerID=8YFLogxK

U2 - 10.1186/s13046-018-0946-5

DO - 10.1186/s13046-018-0946-5

M3 - Article

C2 - 30404651

AN - SCOPUS:85056398297

VL - 37

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 1

ER -